Curated News
By: NewsRamp Editorial Staff
June 02, 2026

Quantum BioPharma's Lucid-MS Could Transform MS Treatment

Discuss on Substack Discuss on Telegram
Original Source

TLDR

  • Quantum BioPharma's Lucid-MS targets an unmet need in MS mobility loss, offering a potential first-mover advantage in nerve repair.
  • Lucid-MS prevents and reverses myelin degradation; Phase 2 trial will test it in MS patients after Phase 1 safety in volunteers.
  • Lucid-MS could restore mobility for MS patients, while unbuzzd helps people metabolize alcohol faster, improving safety and well-being.
  • Quantum BioPharma also sells unbuzzd, a commercial drink that accelerates alcohol metabolism, and earns royalties from its sales.

Impact - Why it Matters

This news matters because multiple sclerosis affects millions worldwide, and current treatments often fail to address mobility loss from nerve damage. Quantum BioPharma's Lucid-MS targets myelin repair, potentially offering a novel therapy that could improve quality of life for MS patients. Additionally, the company's unbuzzd(TM) product provides a practical solution for alcohol metabolism, appealing to health-conscious consumers. The upcoming Phase 2 trial will be a critical step in validating Lucid-MS, making this development relevant to patients, investors, and the broader biotech industry.

Summary

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company dedicated to advancing innovative therapies, was recently featured on The BioMedWire Podcast. Co-founder and executive co-chair Anthony Durkacz discussed the company's lead drug candidate, Lucid-MS, which is being developed to address mobility loss associated with multiple sclerosis by targeting nerve damage. Durkacz emphasized that this area remains unmet by currently available treatments, highlighting the potential of Lucid-MS to fill a critical gap in MS therapy. In addition to its pipeline, Quantum BioPharma has a commercial product, unbuzzd(TM), an alcohol metabolism supplement designed to accelerate blood alcohol breakdown, currently available in the U.S. market. The company is also preparing for an upcoming Phase 2 clinical trial for Lucid-MS, which will be the first study to evaluate the drug candidate in multiple sclerosis patients after Phase 1 testing in healthy volunteers.

Quantum BioPharma is building a portfolio of innovative assets for neurodegenerative, metabolic, and alcohol misuse disorders. Through its wholly owned subsidiary Lucid Psycheceuticals Inc., the company is focused on Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation—the underlying mechanism of multiple sclerosis—in preclinical models. The company also invented UNBUZZD(TM) and spun out its OTC version to Unbuzzd Wellness Inc., retaining a 19.84% ownership stake and a royalty agreement: 7% of sales from unbuzzd(TM) until payments total $250 million, then 3% in perpetuity. Quantum retains 100% of the rights to develop similar products for pharmaceutical and medical uses. The full press release is available at https://ibm.fm/8sLvp.

This news comes as Quantum BioPharma continues to advance its pipeline and commercial products, with a focus on addressing unmet medical needs. The company's approach to MS treatment through myelin repair could represent a significant shift in managing the disease, while unbuzzd(TM) offers a consumer health solution for alcohol metabolism. Investors can find the latest news and updates relating to QNTM in the company’s newsroom at https://ibn.fm/QNTM.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Quantum BioPharma's Lucid-MS Could Transform MS Treatment

blockchain registration record for this content.